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Abstract
Objective: To assess the impact of individualised, reconciled evidence-based recommendations (IRERs) and multidisciplinary
care in patients with chronic heart failure (CHF) on clinical guideline compliance for CHF and common comorbid conditions.
Design and setting: A retrospective hospital clinical audit conducted between 1st July 2006 and February 2011.
Participants: A total of 255 patients with a diagnosis of CHF who attended the Multidisciplinary Ambulatory Consulting
Services (MACS) clinics, at the Royal Adelaide Hospital, were included.
Main outcome measures: Compliance with Australian clinical guideline recommendations for CHF, atrial fibrillation,
diabetes mellitus and ischaemic heart disease.
Results: Study participants had a median of eight medical conditions (IQR 6–10) and were on an average of 10 (64) unique
medications. Compliance with clinical guideline recommendations for pharmacological therapy for CHF, comorbid atrial
fibrillation, diabetes or ischaemic heart disease was high, ranging from 86% for lipid lowering therapy to 98% anti-platelet
agents. For all conditions, compliance with lifestyle recommendations was lower than pharmacological therapy, ranging
from no podiatry reviews for CHF patients with comorbid diabetes to 75% for heart failure education. Concordance with
many guideline recommendations was significantly associated if the patient had IRERs determined, a greater number of
recommendations, more clinic visits or if patients participated in a heart failure program.
Conclusions: Despite the high number of comorbid conditions and resulting complexity of the management, high
compliance to clinical guideline recommendations was associated with IRER determination in older patients with CHF.
Importantly these recommendations need to be communicated to the patient’s general practitioner, regularly monitored
and adjusted at clinic visits.
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Introduction
Chronic heart failure (CHF) occurs in 1.5–2.0% of Austra-
lians.[1] Its incidence and prevalence rise markedly with age; 10%
in people aged $65 years to over 50% in people aged $85
years.[2–3] The presence of comorbidity is common in CHF
patients, with a median of 6 comorbid conditions,[4] and those
with high comorbidity accounts for the majority of inpatient
hospital stays for CHF patients.[5] Highly prevalent cardiac
comorbid conditions in patients with CHF include atrial
fibrillation or flutter (AF), ischaemic heart disease (IHD), and
diabetes mellitus (DM), which are present in 27–75% of patients
with CHF.[6–8] The ageing population and associated increasing
prevalence of comorbidity pose increasing complexity and
challenges in applying clinical guidelines into practice. Most
clinical guidelines are disease specific and often fail to address the
needs of patients with multiple chronic conditions.[9–10] The use
of disease specific guidelines for those with multiple chronic
conditions may in fact be associated with detrimental effects,
including difficult, complicated, inappropriate and harmful
treatment regimens.[4,9].
Multidisciplinary care has been recommended as best-practice
management for patients with CHF.[1,11] There is high level
evidence that demonstrates for those hospitalised for HF,
application of multidisciplinary programs of care significantly
reduces all cause mortality, hospital re-admission, in addition to
improving quality of life for patients and reduced health
expenditure.[1,12] Current evidence supports a number of key
components of multidisciplinary care that can be grouped under
four broad domains, including biomedical care, self-education and
support, psychological care and palliative care, within which
coordination of care and inclusion of agreed treatment and care
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goals are central throughout.[12] For older patients with multiple
conditions, there is a clear need for a multi-disciplinary model of
care which allows incorporation of patient preferences, individu-
alisation of disease specific guideline recommendations, and
reconciles differences and conflicts between them.[13] In this
study we examined the effect of such a model of care, on clinical
guideline compliance in patients with CHF, within the Australian
setting. The influence of common comorbid conditions, including
atrial fibrillation, ischemic heart disease and diabetes and other
patient and clinic-related factors on clinician guideline compliance
were also assessed.
Methods
This study was approved by the Royal Adelaide Hospital
Human Research Ethics Committee. Written consent was given
by the patients for their information to be stored in the hospital
database and used for research purposes.
Study Sample
The study inclusion criteria were all patients with a documented
clinical diagnosis of CHF who attended The Multidisciplinary
Ambulatory Consulting Service (MACS) clinic at a tertiary
teaching hospital from mid 2006 to February 2011. There were
no exclusion criteria. For the purpose of this study, systolic heart
failure (HF) was defined as HF with ejection fraction (EF) #40%
according to the Heart Foundation Guidelines[1], in the absence
of a quantitative assessment, a subjective report of moderate to
severe left ventricular dysfunction. Patients without echocardiog-
raphy, were assumed to have had systolic heart failure.
Study Sample
The MACS is a holistic management model for patients with
multiple comorbidities, that is based on multidisciplinary assess-
ments and the determination of individualised, reconciled
evidence-based recommendations (IRERs). All patients in the
MACS clinic have a holistic assessment consisting of a self-
administered questionnaire which covers living circumstances,
activities of daily living, fall history, vaccination status, appetite
and depression questionnaires. On a clinic visit, patients firstly
have a nursing assessment consisting of an averaged sitting blood
pressure (BP), a standing BP, and social assessment. They then
undergo a medical review by a pharmacist before seeing a
physician. The physician can then generate IRERs using a web-
based database that includes the documented patient specific
information, including comorbid conditions and uses an alogrithm
to resolve variations between evidence-based recommendations
between comorbid conditions and highlight conflict where
resolution is not possible. This results in a reconciled list of
evidence-based recommendations individualised specifically for
each patient (Appendix S1). The recommendations are based on
evidence-based management of CHF from Australian clinical
guidelines including Heart Foundation guidelines[1], and Thera-
peutic Guidelines[14,15], and also included evidence-based
management of common comorbid conditions in CHF including
atrial fibrillation, ischaemic heart disease and diabetes. The core
evidence-based recommendations are seen as the minimum
standard of care which should be considered for all patients
attending the service with that condition. These recommendations
are divided into different categories including pharmacological
(ACE inhibitor and beta blocker therapy, blood thinning, blood
pressure, lipid, and glycaemic control), lifestyle education (exercise,
fluid intake, salt intake, performing daily weighs), investigations,
referrals, action plans and vaccination. The recommendations
based on the evidence based guidelines were then discussed and
agreed upon by the patients and physicians. Responsibility for
attaining these recommendations were determined by the clini-
cian, some assigned to a member of the multi-disciplinary team or
the patient’s general practitioners or the clinician themself.
Determination of Clinician Guideline Compliance
Clinician guideline compliance criteria were developed a priori
and for each patient their applicability, compliance or reason for
non-compliance was assessed cross-sectionally across all patients in
the clinic database as of August 2011, regardless of whether the
patients had ongoing management throughout the clinic. Evidence
based guideline recommendations examined for CHF included;
use of CHF medicines, CHF medicine titrations, development of
individual exercise program, heart failure education, influenza or
pneumococcal vaccination, smoking intervention; anticoagulation
for atrial fibriallation; HbA1c to target in diabetes, use of anti-
platelets, lipids to target in diabetes, blood pressure to target in
diabetes, eye check in diabetes; lipids to target, blood pressure to
target and use of lipid lowering therapy in ischaemic heart disease.
The association of compliance with these guideline recommenda-
tions and patients’ demographic data, patient-related factors
(number of medicines, number of medical problems, Simplified
Nutritional Appetite Questionnaire total[16], Geriatric Depression
Score[17], and number of falls), and clinic-related factors (number
of appointments, whether IRERs were documented or not,
number of IRERs, primary physician, enrolment in a heart failure
program, management by a cardiologist) extracted from the clinic
database, were examined.
Statistical Analysis
Data was analysed using SPSS, version 17.0. Continuous
variables are presented as means 6 standard deviations or as
medians and corresponding 25th and 75th percentiles (interquar-
tiles - IQR). Categorical variables are presented as absolute values
and proportions of patients. To evaluate associations between
comorbid conditions, patient demographics or system factors and
guideline compliance we used student’s t test to analyse normally
distributed data. We used the Mann-Whitney test for ordinal data.
x2- test was used to analyse nominal data. Probability values of p,
0.05 were considered statistically significant.
Results
Baseline Patient Characteristics
A total of 255 patients with a diagnosis of CHF were eligible for
inclusion in the study. Table 1 shows baseline patient character-
istics. The median age was 81 years (IQR 75–86), approximately a
third lived alone (37%). They had a median of 8 comorbid
conditions (IQR 6–10) and were receiving on average 10 (SD64)
different medicines. They were often seen in multiple visits, 4 (IQR
2–8), cardiologists were primary physicians for 21% of patients
while general physicians, geriatricians and clinical pharmacologists
were for the remaining. At the time of the clinician guideline
assessment, 207 patients (81.2%) had completed their manage-
ment through MACS, and the remainder had ongoing appoint-
ments.
Clinician Guideline Compliance
Table 2 shows compliance with clinical guidelines for each
management criteria for CHF, atrial fibrillation, diabetes and
ischaemic heart disease. This included those patients that did not
have any contraindications for guideline recommended manage-
ment strategies. In general there was very good compliance with
Individualised Multidisciplinary Care in CHF
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medication management for CHF and associated comorbid
therapies, with values ranging from 86% for lipid therapy in
those with comorbid ischaemic heart disease to 97% for RAS
antagonists.
Individualised exercise program, HF education, vaccinations,
ophthalmology review, podiatry review, achieving lipids to targets
were the least compliant criteria. When these guideline manage-
ment criteria were grouped according to lifestyle, target-achieving
or medication management, compliance was highest (93.7%) with
medication management (Figure 1).
Patient and Clinic-related Factors Affecting Clinician
Compliance with Guideline Based Recommendations
Associations between the patient demographics and clinical
characteristics and clinician compliance with guideline manage-
ment criteria for HF and comorbid conditions are shown in
Table 3. IRER documentation was significantly associated with
clinician compliance with all guideline recommendations studied,
except for anticoagulation therapy in AF or the use of lipid
lowering therapy in those with comorbid ischaemic heart disease
(Table 3). Similarly increasing numbers of IRERs set was
associated with increased clinician compliance with having an
individualised exercise program, HF education, influenza and
pneumococcal vaccination, anticoagulation for comorbid AF and
HbA1c and lipids to target levels in comorbid diabetes. Enrolment
in a HF program was associated with higher compliance with HF
specific recommendations, including individualised exercise pro-
grams, HF education and influenza vaccination. Higher numbers
of healthcare appointments was also associated with better
clinician compliance with having an exercise program, HF
education, vaccinations and meeting HbA1c to target levels in
comorbid diabetes (Table 3). All other patient and clinical
characteristics investigated were not significantly associated with
any of the guideline management criteria studied (data not shown).
Discussion
The results of this study demonstrate that a multidisciplinary
model of care, utilising individualised, reconciled evidence-based
recommendations, is associated with high clinician compliance to
clinical guideline recommendations, for older patients with HF,
despite the high number of comorbid conditions and resulting
complexity of management and care. The focus on a list of holistic
evidence-based recommendations which are individualised for the
patient, within the context of all medical conditions present,
provides the opportunity to focus on the individual needs of the
patient, rather than individual disease states and for the inclusion
of patient preferences when making treatment decisions. Whilst
current Australian guidelines recommend multidisciplinary care
for people with HF[12], there has been no study to date formally
examining the effects of such care on concordance with guidelines
recommendations, particularly for those with multiple comorbid
conditions. This is the first study to examine clinical guideline
compliance for CHF and comorbid conditions, in a multidisci-
plinary model of care.
The clinician compliance with guideline recommendations
using this model of care for these complex patients, was better
than that reported in previous studies focused on managing
isolated CHF. In the IMPORVE HF study[18] in outpatient
cardiology practices in US, compliance with RAS antagonists was
79%, beta-blockers was 87.6%, HF education was 60.7%, and
with anticoagulation in AF was 70%. In a European study[6]
across 24 countries of 3658 patients with a diagnosis of left
ventricular systolic dysfunction, they found compliance to RAS
inhibitors and beta blockers was between 80–86% and 42–63%,
respectively. In the CASE study[19] on 2905 CHF patients in
Australian general practices, rates of ACEI, ARB, and beta-
blocker uses were 70.7%, 6.4% and 13.9%, respectively. In a study
of CHF inpatients admitted to the same venue as the current
study, at the time of discharge, 59% of patients were on ACEIs,
Table 1. Baseline Characteristics of CHF Patients (n = 255).
Characteristics N (%) (unless stated otherwise)
Demographics
Age (median, IQR) 81 (75–86)
Female 136 (53%)
Lives alone 94 (37%)
Clinical characteristics
Systolic heart failure 109 (43%)
Number of documented medical conditions (median and IQR) 8 (6–10)
Patients with documented IRERs 235 (92%)
Number of medicines on presentation (mean and SD) 1064
Total number of appointments 4 (2–8)
SNAQ total 14 (12–16)
Geriatric depression score 5 (2–8)
Seen by a cardiologist 63 (21%)
Seen by a consultant 246 (96%)
Falls (total patients) 196
0 falls 106 (54%)
1–2 falls 63 (32%)
.2 falls 27 (14%)
IQR, Interquartile range; IRERs, individualised reconciled evidence-based recommendations; SNAQ, Simplified Nutritional Appetite Questionnaire.
doi:10.1371/journal.pone.0093129.t001
Individualised Multidisciplinary Care in CHF
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Table 2. Compliance with clinical guideline recommendations for CHF patients.
Management criterion Patients should have the management N{ Compliance N (%)
Chronic heart failure n=255
RAS antagonist 90 87 (97%)
Maximized dose 82 (94%)
Betablockers 98 91 (93%)
Maximized dose 87 (96%)
Exercise program 195 70 (36%)
Heart failure education 226 170 (75%)
Influenza vaccination 208 170 (82%)
Pneumococcal vaccination 183 116 (63%)
Atrial fibrillation n=122
Anticoagulation 79 69 (87%)
Diabetes mellitus n=114
HbA1c to target 114 92 (81%)
Any lipid therapy 68 62 (91%)
Lipids to target 50 (74%)
BP to target 100 91 (91%)
Ophthalmology review 69 24 (35%)
Podiatry review 109 0 (0%)
Ischaemic heart disease n=147
Anti-platelet 139 136 (98%)
Any lipid therapy 94 81 (86%)
Lipids to target 69 (73%)
BP to target 130 122 (94%)
Smoking intervention 10 9 (90%)
{number represents total number of patients with indication and no contraindication for guideline based management.
doi:10.1371/journal.pone.0093129.t002
Figure 1. Proportion of CHF patients compliant with clinical guidelines recommendations grouped lifestyle, target-achieving and
pharmacological management.
doi:10.1371/journal.pone.0093129.g001
Individualised Multidisciplinary Care in CHF
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Table 3. Factors significantly affecting compliance with clinical guideline recommendations.
Patient or Clinical Characteristic Guideline Recommendation p value
Exercise (n =195)
Compliant (n = 70) Non-compliant (n = 125)
Age (Median, IQR) 79 (71–84) 82 (75–86) 0.036
Enrolment in heart failure program 33 (47%) 25 (20%) ,0.001
IRERs determined 68 (97%) 107 (86%) 0.012
Number of IRERs (Mean 6 SD) 24610 17611 ,0.001
Number of appointments (Median, IQR) 6 (4–11) 3 (2–7) ,0.001
Heart failure education (n =226)
Compliant (n = 170) Non-compliant (n = 56)
Enrolment in heart failure program 73 (43%) 1 (2%) ,0.001
IRERs determined 167 (98%) 39 (70%) ,0.001
Number of IRERs (Mean 6 SD) 24620 1069 ,0.001
Numbers of appointments (Median, IQR) 5 (3–10) 2 (1–3) ,0.001
Management by a cardiologist 48 (28%) 4 (7%) 0.001
Lives alone 54 (32%) 28 (50%) 0.017
Influenza vaccination (n =208)
Compliant (n = 170) Non-compliant (n = 38)
Age (Median, IQR) 80 (78–86) 79 (69–84) 0.02
Enrolment in heart failure program 59 (35%) 4 (11%) 0.003
IRERs determined 161 (95%) 27 (71%) ,0.001
Number of IRERs (Mean 6 SD) 22610 11611 ,0.001
Numbers of appointments (Median, IQR) 5 (3–10) 2 (1–3) ,0.001
Pneumococcal vaccination (n=183)
Compliant (n = 116) Non-compliant (n = 67)
IRERs determined 108 (93%) 55 (82%) 0.027
Number of IRERs (Mean 6 SD) 24610 17611 ,0.001
Numbers of appointments (Median, IQR) 5 (3–11) 3 (2–5) ,0.001
Anticoagulation for AF (n =79)
Compliant (n = 69) Non-compliant (n = 10)
Age (Median, IQR) 81 (76–85) 85 (81–94) 0.025
Number of IRERs (Mean 6 SD) 20611 969 0.004
Meet HbA1c target in diabetes (n =114)
Compliant (n = 92) Non-compliant (n = 22)
IRERs determined 90 (98%) 15 (68%) ,0.001
Number of IRERs (Mean 6 SD) 2569 17613 0.011
Numbers of appointments (Median, IQR) 5.5 (3–11) 3 (1–6.3) 0.021
Lipids to target in diabetes (n =68)
Compliant (n = 50) Non-compliant (n = 18)
IRERs determined 46 (92%) 13 (72%) 0.048
Number of IRERs (Mean 6 SD) 25611 15612 0.007
Numbers of appointments (Median, IQR) 6 (2.8–11) 3 (1.8–4.3) 0.028
Blood pressure to target in diabetes (n =100)
Compliant (n = 91) Non-compliant (n = 9)
IRERs determined 85 (93%) 6 (67%) 0.033
Eye checked in diabetes (n =69)
Compliant (n = 24) Non-compliant (n = 45)
IRERs determined 24 (100%) 36 (80%) 0.022
Management by a cardiologist 46% 20% 0.03
Lipid lowering therapy in ischemic heart disease (n=94)
Compliant (n = 81) Non-compliant (n = 13)
Individualised Multidisciplinary Care in CHF
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and 43% were on beta-blockers. These patients were not seen in
cardiology or MACS clinics.[7]. Although multidisciplinary care
and an increased awareness of the benefits of CHF management
may have contributed to our results, a consistent finding in our
data was the positive association between the determination of
IRERs and clinician guideline compliance. The determination of
the IRERs, and their modification and further individualisation
based on patient preferences, has many benefits in the manage-
ment of multimorbid patients. This includes a basis for discussion
of patient centred goals and patient preferences; provision of
decision support for the large number of diverse evidence-based
recommendations for complex patients; it acts as a prompt and a
checklist for keeping patients on track for achieving treatment
outcomes when they have disease exacerbations or admissions
which may interrupt their routine outpatient management. In
addition, the high adherence to guideline recommendations (both
pharmacological and non-pharmacological) in our study and a
willingness to participate in healthier behaviours may have been
facilitated by the multidisciplinary model of care, together with the
provision of IRERs. Medication adherence has previously been
reported as a marker for adherence to other treatments or
behaviours that may affect health outcomes.[20,21].
In our current study, clinician adherence to pharmacological
treatment recommendations was greater than that observed for
lifestyle measures. Often lifestyle consultations consume greater
time and effort than starting patients on medicines and
commencement of pharmacological therapies may also be better
documented than lifestyle measures. The MACS clinic was
developed by the Clinical Pharmacology department, in the study
hospital, as an identified need to manage polypharmacy and the
intervention gap in HF management, hence medications are a
focus. The outcomes may have been different if a dietician or
exercise physiologist was a member of the team instead of a
pharmacist. Further, recommendations requiring the achievement
of specific targets which generally require multiple steps such as
achieving BP, lipid or glycated Hb targets, were not performed as
well as single-step interventions. Another factor which appeared to
influence guideline compliance ambiguity of whether the primary
responsibility for an intervention sat within the MACS clinic or in
primary care, for example vaccinations and referrals to ophthal-
mologists and podiatrists. None of diabetic patients had a
documented podiatry review however, this was not included in
our clinic core recommendations. This highlights the role of the
recommendations in acting as a reminder for guideline based
management, as well as helping support documentation of
outcomes.
Whilst we observed that IRER determination within multidis-
ciplinary care was associated with increased compliance with
guideline recommendations, the number of visits was also
significantly associated with improved clinician uptake of guideline
recommendations. When visits reached five to six times, many
additional core managements occurred. This highlights the
complexity of this patient population, and the fact that in order
to achieve evidence-based recommendations, a substantial clinical
investment has to be made.
The study highlighted areas where care that could be improved.
Dedicating a nurse to initiate lifestyle measures may bring better
adherence into these aspects. Although increased number of clinic
visits was associated with higher guideline compliance in many
aspects, patients who are compliant are likely to be seen more
times and more likely to have all of their recommendations met.
Managing patients with multiple comorbidities as it is largely a
step-wise process. Each change usually occur one step at a time. A
system for documentation of the change and communication to
other team members is vital especially as the process of care is
often interrupted by disease exacerbations, and other social and
psychological interferences.
Our study has several limitations. The study was based on a
clinic database, making it difficult to compare with previous
studies where mainly case-note reviews were used. Due to the
design of the MACS clinic and the current study, whereby there
were no exclusion criteria for the cohort selection, it was not
possible to compare our results with an internal control group.
The clinic attracts referrals of complex multimorbid patients with
CHF and a comparable cohort of patients in other hospital
outpatient clinics who were not referred to the MACS clinic were
not able to be identified. Furthermore, the cohort of patients in the
MACS clinics do not represent a general outpatient population.
These patients selectively have multiple comorbid conditions,
where multidisciplinary team and multiple appointments are
probably more useful in this setting, and this may have biased the
referral patterns for patients more likely to respond. The provision
of care received within the hospital setting is likely to be different
to that received within community settings and as a result patients
may have been more likely to participate in self-care, resulting in
improved outcomes.
In conclusion, provision of multi-disciplinary care utilising
individualised reconciled evidence-based recommendations for
older patients with CHF and multiple comorbid conditions,
resulted in high clinician compliance with clinical guideline
recommendations. In an era of increasing focus on patient-centred
care, the inclusion of patient preference and circumstance in
formulating goals for healthcare is of increasing importance,
particularly for those with multiple conditions.
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Table 3. Cont.
Patient or Clinical Characteristic Guideline Recommendation p value
Age (Median, IQR) 79 (74.5–83) 83 (79–88.5) 0.014
IRERs, individualised reconciled evidence-based recommendations.
doi:10.1371/journal.pone.0093129.t003
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